The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

John J. V. McMurray

British Heart Foundation Glasgow Cardiovascular Research Centre

University of Glasgow

Glasgow

G12 8TA

UK

[email]@bio.gla.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK. 2008 - 2010
  • Department of Cardiology, Western Infirmary, Glasgow, G12 8QQ, United Kingdom. 2002 - 2007
  • University of Glasgow, Scotland. 2005
  • University of Glasgow, Glasgow, G12 8QQ, UK. 2000 - 2003
  • Clinical Research Initiative in Heart Failure, Glasgow, Scotland G11 6NT, UK. 2001 - 2002
  • CRI in Heart Failure, Wolfson Building, University of Glasgow, Glasgow G12 8QQ. 1999 - 2001

References

  1. Clinical practice. Systolic heart failure. McMurray, J.J. N. Engl. J. Med. (2010) [Pubmed]
  2. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. McMurray, J.J., Kjekshus, J., Gullestad, L., Dunselman, P., Hjalmarson, A., Wedel, H., Lindberg, M., Waagstein, F., Grande, P., Hradec, J., Kamenský, G., Korewicki, J., Kuusi, T., Mach, F., Ranjith, N., Wikstrand, J. Circulation (2009) [Pubmed]
  3. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. McMurray, J.J., Anand, I.S., Diaz, R., Maggioni, A.P., O'Connor, C., Pfeffer, M.A., Polu, K.R., Solomon, S.D., Sun, Y., Swedberg, K., Tendera, M., van Veldhuisen, D.J., Wasserman, S.M., Young, J.B. Eur. J. Heart Fail. (2009) [Pubmed]
  4. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. McMurray, J.J., Pitt, B., Latini, R., Maggioni, A.P., Solomon, S.D., Keefe, D.L., Ford, J., Verma, A., Lewsey, J. Circ. Heart. Fail (2008) [Pubmed]
  5. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. McMurray, J.J., Teerlink, J.R., Cotter, G., Bourge, R.C., Cleland, J.G., Jondeau, G., Krum, H., Metra, M., O'Connor, C.M., Parker, J.D., Torre-Amione, G., van Veldhuisen, D.J., Lewsey, J., Frey, A., Rainisio, M., Kobrin, I. JAMA (2007) [Pubmed]
  6. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). McMurray, J., Solomon, S., Pieper, K., Reed, S., Rouleau, J., Velazquez, E., White, H., Howlett, J., Swedberg, K., Maggioni, A., Køber, L., Van de Werf, F., Califf, R., Pfeffer, M. J. Am. Coll. Cardiol. (2006) [Pubmed]
  7. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. McMurray, J.J., Young, J.B., Dunlap, M.E., Granger, C.B., Hainer, J., Michelson, E.L., Earle, S., Olofsson, B., Ostergren, J., Yusuf, S., Swedberg, K., Pfeffer, M.A. Am. Heart J. (2006) [Pubmed]
  8. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. McMurray, J.J., Andersson, F.L., Stewart, S., Svensson, K., Solal, A.C., Dietz, R., Vanhaecke, J., van Veldhuisen, D.J., Ostergren, J., Granger, C.B., Yusuf, S., Pfeffer, M.A., Swedberg, K. Eur. Heart J. (2006) [Pubmed]
  9. Treatment of chronic heart failure: a comparison between the major guidelines. McMurray, J., Swedberg, K. Eur. Heart J. (2006) [Pubmed]
  10. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. McMurray, J., Køber, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, D.N., Ford, I. J. Am. Coll. Cardiol. (2005) [Pubmed]
  11. Heart failure. McMurray, J.J., Pfeffer, M.A. Lancet (2005) [Pubmed]
  12. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. McMurray, J., Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, F.D., Krum, H., Maggioni, A., McKelvie, R.S., Piña, I.L., Soler-Soler, J., Swedberg, K. Eur. J. Heart Fail. (2005) [Pubmed]
  13. Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment. McMurray, J.J. Kidney Int. (2005) [Pubmed]
  14. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?. McMurray, J.J. Nature Clinical Practice. Cardiovascular Medicine (2005) [Pubmed]
  15. Angiotensin inhibition in heart failure. McMurray, J.J. J. Renin. Angiotensin. Aldosterone. Syst (2004) [Pubmed]
  16. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?. McMurray, J.J., Pfeffer, M.A., Swedberg, K., Dzau, V.J. Circulation (2004) [Pubmed]
  17. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. McMurray, J., Ostergren, J., Pfeffer, M., Swedberg, K., Granger, C., Yusuf, S., Held, P., Michelson, E., Olofsson, B. Eur. J. Heart Fail. (2003) [Pubmed]
  18. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. McMurray, J.J., Ostergren, J., Swedberg, K., Granger, C.B., Held, P., Michelson, E.L., Olofsson, B., Yusuf, S., Pfeffer, M.A. Lancet (2003) [Pubmed]
  19. New therapeutic options in congestive heart failure: Part II. McMurray, J., Pfeffer, M.A. Circulation (2002) [Pubmed]
  20. Heart failure in 10 years time: focus on pharmacological treatment. McMurray, J.J. Heart (2002) [Pubmed]
  21. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. McMurray, J.J. Heart (2001) [Pubmed]
  22. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. McMurray, J., Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, R., Maggioni, A., Pina, I., Soler-Soler, J., Swedberg, K. Eur. J. Heart Fail. (2001) [Pubmed]
  23. Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?. McMurray, J.J. J. Renin. Angiotensin. Aldosterone. Syst (2001) [Pubmed]
  24. Epidemiology, aetiology, and prognosis of heart failure. McMurray, J.J., Stewart, S. Heart (2000) [Pubmed]
  25. AT(1) receptor antagonists-beyond blood pressure control: possible place in heart failure treatment. McMurray, J. Heart (2000) [Pubmed]
  26. Why we need new strategies in CHF management. McMurray, J. J. Renin. Angiotensin. Aldosterone. Syst (2000) [Pubmed]
  27. Major beta blocker mortality trials in chronic heart failure: a critical review. McMurray, J.J. Heart (1999) [Pubmed]
 
WikiGenes - Universities